Novartis Ag (NVS) Receivables Refunds (2016 - 2025)
Historic Receivables Refunds for Novartis Ag (NVS) over the last 10 years, with Q4 2025 value amounting to $205.0 million.
- Novartis Ag's Receivables Refunds rose 5413.53% to $205.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $205.0 million, marking a year-over-year increase of 5413.53%. This contributed to the annual value of $205.0 million for FY2025, which is 5413.53% up from last year.
- Novartis Ag's Receivables Refunds amounted to $205.0 million in Q4 2025, which was up 5413.53% from $140.0 million recorded in Q3 2025.
- Novartis Ag's 5-year Receivables Refunds high stood at $426.0 million for Q4 2023, and its period low was $120.0 million during Q2 2025.
- Its 5-year average for Receivables Refunds is $248.0 million, with a median of $256.5 million in 2021.
- Its Receivables Refunds has fluctuated over the past 5 years, first surged by 5895.52% in 2023, then crashed by 6877.93% in 2024.
- Quarter analysis of 5 years shows Novartis Ag's Receivables Refunds stood at $278.0 million in 2021, then decreased by 3.6% to $268.0 million in 2022, then soared by 58.96% to $426.0 million in 2023, then crashed by 68.78% to $133.0 million in 2024, then soared by 54.14% to $205.0 million in 2025.
- Its last three reported values are $205.0 million in Q4 2025, $140.0 million for Q3 2025, and $120.0 million during Q2 2025.